Praxis receives FDA alignment on ulixacaltamide NDA submission plans
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
Praxis Precision Medicines Inc. (PRAX) PT Raised to $500 at Truist Securities
December 8, 2025 6:26 AM ESTTruist Securities analyst Joon Lee raised the price target on Praxis Precision Medicines Inc. (NASDAQ: PRAX) to $500.00 (from $360.00) while maintaining a Buy rating.
The analyst comments "Vormatrigine reported 100% median seizure reduction at week 8, which was sustained through wk 16 in full Ph2 RADIANT. The results... More
